Pharmaceuticals - P&GP Compliance Policy and Declaration

United States

P&G Network Search

Pharmaceuticals:
US Products

Consumers:

Health Care Professionals:

FDA APPROVES NEW ONCE-A-MONTH DOSE OF ACTONEL FOR POSTMENOPAUSAL OSTEOPOROSIS

CINCINNATI, Bridgewater, NJ, April 24, 2008 — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel� (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
More:

At P&G Pharmaceuticals, it is our policy to operate in compliance with every applicable federal and state law related to the manufacturing, marketing and promotion of our products in the US. We have a well-established compliance program that echoes our long-term commitment to comply with the law.

For more information about P&GP's Compliance Policy click here

Declaration

Read P&GP's Declaration

P&GP Authorized Distributor List

For a detailed list of our authorized distributors, click here

Declaration

For a list of European patient organisations with whom we have a relationship, please click here




	©2008 Procter & Gamble. All claims valid only in the U.S. Legal Information Privacy Statement P&G Links